J&J asks MHRA for antifungal switch
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
You may also be interested in...
Johnson & Johnson President Brings Extensive McNeil Background To Post
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.